Want to stay updated on the latest news?
Create a Reader Account today to follow the industries and companies that interest you, and customize your news dashboard. SIGN INTO READER ACCOUNT CREATE READER ACCOUNT
Cerevel Therapeutics to Present at the Stifel 2023 CNS Days
March 21, 2023 06:30 ET
|
Cerevel Therapeutics
CAMBRIDGE, Mass., March 21, 2023 (GLOBE NEWSWIRE) -- Cerevel Therapeutics, (Nasdaq: CERE), a company dedicated to unraveling the mysteries of the brain to treat neuroscience diseases, today...
Cerevel Therapeutics to Present at the 43rd Annual Cowen Health Care Conference
March 02, 2023 06:30 ET
|
Cerevel Therapeutics
CAMBRIDGE, Mass., March 02, 2023 (GLOBE NEWSWIRE) -- Cerevel Therapeutics, (Nasdaq: CERE), a company dedicated to unraveling the mysteries of the brain to treat neuroscience diseases, today...
Cerevel Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Business Updates
February 22, 2023 06:30 ET
|
Cerevel Therapeutics
Emraclidine Phase 1 healthy elderly volunteer trial enrollment underway to support development in Alzheimer’s disease psychosis Emraclidine Phase 2 schizophrenia data readout remains on track for 1H...
Cerevel Therapeutics to Report Fourth Quarter and Full Year 2022 Financial Results and Business Updates on Wednesday, February 22, 2023
February 01, 2023 06:30 ET
|
Cerevel Therapeutics
CAMBRIDGE, Mass., Feb. 01, 2023 (GLOBE NEWSWIRE) -- Cerevel Therapeutics (Nasdaq: CERE), a company dedicated to unraveling the mysteries of the brain to treat neuroscience diseases, today announced...
Cerevel Therapeutics to Present at 41st Annual J.P. Morgan Healthcare Conference and Provide Pipeline Update
January 09, 2023 06:30 ET
|
Cerevel Therapeutics
Initiated Phase 1 healthy volunteer trial to support development of emraclidine in Alzheimer’s disease psychosis in Q4 2022; second potential indication as a once-daily treatment Phase 2...
Cerevel Therapeutics to Present at the 41st Annual J.P. Morgan Healthcare Conference
January 04, 2023 06:30 ET
|
Cerevel Therapeutics
CAMBRIDGE, Mass., Jan. 04, 2023 (GLOBE NEWSWIRE) -- Cerevel Therapeutics, (Nasdaq: CERE), a company dedicated to unraveling the mysteries of the brain to treat neuroscience diseases, today announced...
Cerevel Therapeutics Announces Positive Results in Emraclidine Ambulatory Blood Pressure Monitoring Trial
December 19, 2022 06:30 ET
|
Cerevel Therapeutics
Data provide clear evidence that emraclidine does not induce an increase in blood pressure with chronic dosing in people living with schizophrenia Emraclidine demonstrated a mean change from baseline...
Cerevel Therapeutics Announces Publication in The Lancet of Emraclidine Data from Phase 1b Clinical Trial in People Living with Schizophrenia
December 15, 2022 18:30 ET
|
Cerevel Therapeutics
Emraclidine is being developed as a potential once-daily treatment for schizophrenia without the need for titration Data show clinically meaningful and statistically significant improvement with...
Cerevel Therapeutics to Present at Upcoming Investor Conferences
November 11, 2022 06:30 ET
|
Cerevel Therapeutics
CAMBRIDGE, Mass., Nov. 11, 2022 (GLOBE NEWSWIRE) -- Cerevel Therapeutics, (Nasdaq: CERE), a company dedicated to unraveling the mysteries of the brain to treat neuroscience diseases, announced that...
Cerevel Therapeutics Reports Third Quarter 2022 Financial Results and Business Updates
November 08, 2022 06:30 ET
|
Cerevel Therapeutics
Completed $599 million dual convertible debt and equity financing to advance a robust neuroscience therapeutics pipeline Initiated EMPOWER-3, a 52-week open-label extension trial of emraclidine in...